The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

被引：50

作者：

Albers, C. ^{[1
]}

Leischner, H. ^{[1
]}

Verbeek, M. ^{[1
]}

Yu, C. ^{[1
]}

Illert, A. L. ^{[2
]}

Peschel, C. ^{[1
]}

von Bubnoff, N. ^{[2
]}

Duyster, J. ^{[2
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 3, D-80290 Munich, Germany

[2] Univ Med Ctr Freiburg, Dept Hematol Oncol, Freiburg, Germany

来源：

LEUKEMIA | 2013年 / 27卷 / 06期

关键词：

ACUTE MYELOID-LEUKEMIA; CLINICAL RESISTANCE; INHIBITORS; SORAFENIB;

D O I：

10.1038/leu.2013.14

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1416 / 1418

页数：4

共 8 条

[1] Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia [J].

Cools, J ;

Mentens, N ;

Furet, P ;

Fabbro, D ;

Clark, JJ ;

Griffin, JD ;

Marynen, P ;

Gilliland, DG .

CANCER RESEARCH, 2004, 64 (18) :6385-6389

[2] Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain [J].

Heidel, F ;

Solem, FK ;

Breitenbuecher, F ;

Lipka, DB ;

Kasper, S ;

Thiede, MH ;

Brandts, C ;

Serve, H ;

Roesel, J ;

Giles, F ;

Feldman, E ;

Ehninger, G ;

Schiller, GJ ;

Nimer, S ;

Stone, RM ;

Wang, YF ;

Kindler, T ;

Cohen, PS ;

Huber, C ;

Fischer, T .

BLOOD, 2006, 107 (01) :293-300

[3] Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations [J].

Kancha, Rama Krishna ;

Grundler, Rebekka ;

Peschel, Christian ;

Duyster, Justus .

EXPERIMENTAL HEMATOLOGY, 2007, 35 (10) :1522-1526

[4] Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns [J].

Moore, A. S. ;

Faisal, A. ;

de Castro, D. Gonzalez ;

Bavetsias, V. ;

Sun, C. ;

Atrash, B. ;

Valenti, M. ;

Brandon, A. de Haven ;

Avery, S. ;

Mair, D. ;

Mirabella, F. ;

Swansbury, J. ;

Pearson, A. D. J. ;

Workman, P. ;

Blagg, J. ;

Raynaud, F. I. ;

Eccles, S. A. ;

Linardopoulos, S. .

LEUKEMIA, 2012, 26 (07) :1462-1470

[5] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia [J].

Smith, Catherine C. ;

Wang, Qi ;

Chin, Chen-Shan ;

Salerno, Sara ;

Damon, Lauren E. ;

Levis, Mark J. ;

Perl, Alexander E. ;

Travers, Kevin J. ;

Wang, Susana ;

Hunt, Jeremy P. ;

Zarrinkar, Patrick P. ;

Schadt, Eric E. ;

Kasarskis, Andrew ;

Kuriyan, John ;

Shah, Neil P. .

NATURE, 2012, 485 (7397) :260-U153

[6] Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib [J].

von Bubnoff, N. ;

Rummelt, C. ;

Menzel, H. ;

Sigl, M. ;

Peschel, C. ;

Duyster, J. .

LEUKEMIA, 2010, 24 (08) :1523-1525

[7] FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro [J].

von Bubnoff, Nikolas ;

Engh, Richard A. ;

Aberg, Espen ;

Sanger, Jana ;

Peschel, Christian ;

Duyster, Justus .

CANCER RESEARCH, 2009, 69 (07) :3032-3041

[8] AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) [J].

Zarrinkar, Patrick P. ;

Gunawardane, Ruwanthi N. ;

Cramer, Merryl D. ;

Gardner, Michael F. ;

Brigham, Daniel ;

Belli, Barbara ;

Karaman, Mazen W. ;

Pratz, Keith W. ;

Pallares, Gabriel ;

Chao, Qi ;

Sprankle, Kelly G. ;

Patel, Hitesh K. ;

Levis, Mark ;

Armstrong, Robert C. ;

James, Joyce ;

Bhagwat, Shripad S. .

BLOOD, 2009, 114 (14) :2984-2992

← 1 →